| [1] |
Hueman MT, Vollmer CM, Pawlik TM. Evolving treatment strategies for gallbladder cancer[J]. Ann Surg Oncol, 2009, 16(8):2101-2115.
|
| [2] |
Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update[J]. Ann Oncol, 2009, 20(1):146-159.
|
| [3] |
Butte JM, Matsuo K, Gönen M, et al. Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries[J]. J Am Coll Surg, 2011, 212(1):50-61.
|
| [4] |
Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer[J]. Gut Liver, 2012, 6(2):172-187.
|
| [5] |
Witjes CDM, van den Akker SAW, Visser O, et al. Gallbladder cancer in the Netherlands: incidence, treatment and survival patterns since 1989[J]. Dig Surg, 2012, 29(2):92-98.
|
| [6] |
Are C, Ahmad H, Ravipati A, et al. Global epidemiological trends and variations in the burden of gallbladder cancer[J]. J Surg Oncol, 2017, 115(5):580-590.
|
| [7] |
Narayan RR, Creasy JM, Goldman DA, et al. Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations[J]. Cancer, 2019, 125(4):575-585.
|
| [8] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA A Cancer J Clinicians, 2019, 69(1):7-34.
|
| [9] |
Lazcano-Ponce EC, Miquel JF, Muñoz N, et al. Epidemiology and molecular pathology of gallbladder cancer[J]. CA Cancer J Clin, 2001, 51(6):349-364.
|
| [10] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clinicians, 2016, 66(2):115-132.
|
| [11] |
Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder[J]. Lancet Oncol, 2003, 4(3):167-176.
|
| [12] |
Levy AD, Murakata LA, Jr Rohrmann CA. Gallbladder carcinoma: radiologic-pathologic correlation[J]. Radiographics, 2001, 21(2):295-314.
|
| [13] |
Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw, 2021, 19(5):541-565.
|
| [14] |
Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: current status and emerging strategies[J]. World J Gastrointest Oncol, 2015, 7(11):338-346.
|
| [15] |
Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy[J]. Nat Rev Cancer, 2017, 17(5):286-301.
|
| [16] |
Kong W, Wei J, Liu J, et al. Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report[J]. Onco Targets Ther, 2019, 12: 5389-5393.
|
| [17] |
Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy[J]. Sci Transl Med, 2020, 12(534):eaav7431.
|
| [18] |
Kawamoto M, Wada Y, Koya N, et al. Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report[J]. Surg Case Rep, 2018, 4(1):115.
|
| [19] |
Bhamare S, Prabhakar P, Dharmadhikari A, et al. Autologous immune enhancement therapy in a case of gall bladder cancer stage Ⅳafter surgical resection and chemotherapy yielding a stable non-progressive disease[J]. J Cancer Res Ther, 2014, 10(3):752-754.
|
| [20] |
Li J, Wei Q, Wu X, et al. Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response[J]. Clin Transl Med, 2020, 10(4):e118.
|
| [21] |
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-2454.
|
| [22] |
Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy[J]. Future Oncol, 2021, 17(7):755-757.
|
| [23] |
Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer[J]. Cancer Manag Res, 2018, 10: 931-940.
|
| [24] |
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212):1929-1939.
|
| [25] |
Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors[J]. Clin Cancer Res, 2019, 25(13):3753-3758.
|
| [26] |
Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site-when a biomarker defines the indication[J]. N Engl J Med, 2017, 377(15):1409-1412.
|
| [27] |
Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature, 2017, 547(7662):217-221.
|
| [28] |
Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J]. Nature, 2017, 547(7662):222-226.
|
| [29] |
Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma[J]. Nature, 2019, 565(7738):240-245.
|
| [30] |
Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer[J]. Sci Transl Med, 2018, 10(436):eaao5931.
|
| [31] |
Chen X, Wang D, Liu J, et al.Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes[J].J Immunother Cancer, 2021, 9(11):e003214.
|
| [32] |
Chen X, Wu X, Wu H, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phaseⅡ trial[J]. J Immunother Cancer, 2020, 8(2):e001240.
|